Healthcare & pharma stocks — P/E and P/S valuations
Compare global pharmaceutical, biotech, and healthcare leaders by trailing P/E, latest-quarter P/E, and P/S.
| ticker | company | P/E · trailing | P/E · quarter | P/S · trailing | market cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly & Co | 45.9 | 49.1 | 14.7 | US$1.27tn |
| JNJ | Johnson & Johnson | 40.5 | 775.1 | 6.6 | US$651.11bn |
| ABBV | AbbVie Inc | 49.1 | 30.1 | 7.7 | US$505.89bn |
| UNH | UnitedHealth Group Inc | 19.2 | 18.5 | 0.7 | US$304.51bn |
| NVO | NOVO NORDISK CLASS B | 8.8 | 5.5 | 3.3 | US$168.87bn |
| MRK | Merck & Co Inc | 134.4 | 16.3 | 4.9 | US$329.65bn |
| PFE | Pfizer Inc | 36.0 | -157.4 | 2.5 | US$156.17bn |
| AZN | ASTRAZENECA PLC | 26.1 | 27.2 | 4.4 | US$272.33bn |
Frequently asked questions
Why do pharma P/E ratios vary so widely?
High-growth drug pipelines (such as obesity and oncology leaders) often trade at higher multiples, while mature patent-cliff portfolios trade at lower P/E ratios.
More stock categories
Sources and methodology
Every stock P/E and P/S ratio is calculated directly from price, share count, and reported company earnings and revenue, normalised to USD. Informational research, not investment advice.
Browse all stocks Read investor guides